MIT engineers have developed a groundbreaking implantable device for type 1 diabetes treatment that contains its own "on-board oxygen factory." This innovation addresses the challenge of ensuring transplanted pancreatic islet cells receive sufficient oxygen to produce insulin. The device, roughly the size of a US quarter, has shown promising results in diabetic mice, maintaining stable glucose levels for at least a month. While further testing is needed, this technology offers hope for a more manageable and less invasive treatment for type 1 diabetics.
Photo Credit: Dennis Klicker